In his roles, Dr. Carpenter will “unite Speros and Moffitt’s clinical and research expertise with commercial partners to accelerate breakthroughs in cancer prevention and treatment,” according to a March 11 news release from Moffitt.
“With his guidance, we will shape Speros into a global model for groundbreaking discoveries and patient outcomes,” Patrick Hwu, MD, Moffitt president and CEO, said in the release.